Surgery of locally advanced and metastatic kidney cancer after tyrosine kinase inhibitors therapy: single institute experience



Renal cell carcinoma (RCC) is the most common tumor of the kidney. Considering the TNM classification of 2009, locally advanced and metastatic diseases are included in the groups stage III and IV. The surgical treatment of these tumors could be divided into 3 categories: (1) curative (nephrectomy and/or metastasectomy), (2) cytoreductive, and (3) palliative. Targeted agents showed impressive antitumor efficacy and prolongation of progression-free survival. The integration between target therapy and surgery in patients with locally advanced or metastatic RCC has sometimes facilitated surgery. We aimed to evaluate patients’ response to tyrosine kinase inhibitor (TKI) therapy and the feasibility of surgery after that and to observe complications related to surgery.


From February 2007 to September 2014 in the Istituto Tumori of Milan, IRCCS, we selected patients with locally advanced or metastatic diseases, treated with target therapy before surgery (which comprised nephrectomy or partial nephrectomy, cytoreductive surgery, and metastasectomy) and cryoablation.


We selected 33 patients who underwent surgery after TKI therapy. As for response to TKIs, 20 patients (60%) had stable disease, 9 patients (28%) had a partial response, and 4 patients (12%) had progressive disease. A total of 17 patients (51%) presented complications directly or indirectly related to surgery and most of those were classified as grade II Clavien-Dindo score.


The association between TKI and surgery seems to have no contraindications. Our dataset provides an example of how surgery after TKI is possible in locally advanced metastatic tumor and does not have an excessive rate of postoperative complications.

Post author correction




Alberto De Gobbi, Davide Biasoni, Mario Catanzaro, Nicola Nicolai, Luigi Piva, Silvia Stagni, Tullio Torelli, Giuseppe Procopio, Elena Verzoni, Paolo Grassi, Maurizio Colecchia, Biagio Paolini, Carlo Spreafico, Alfonso Marchianò, Roberto Salvioni

Article History


Financial support: No financial support was received for this submission.
Conflict of interest: None of the authors has conflict of interest with this submission.

This article is available as full text PDF.

  • If you are a Subscriber, please log in now.

  • Article price: Eur 36,00
  • You will be granted access to the article for 72 hours and you will be able to download any format (PDF or ePUB). The article will be available in your login area under "My PayPerView". You will need to register a new account (unless you already own an account with this journal), and you will be guided through our online shop. Online purchases are paid by Credit Card through PayPal.
  • If you are not a Subscriber you may:
  • Subscribe to this journal
  • Unlimited access to all our archives, 24 hour a day, every day of the week.



  • Department of Urology, Fondazione IRCCS Istituto dei Tumori, Milan - Italy
  • Department of Oncology, Fondazione IRCCS Istituto dei Tumori, Milan - Italy
  • Department of Pathology, Fondazione IRCCS Istituto dei Tumori, Milan - Italy
  • Department of Radiology, Fondazione IRCCS Istituto dei Tumori, Milan - Italy
  • Current affiliation: Department of Urology, Treviso Hospital, Ulss 2 Marca Trevigiana, Treviso - Italy

Article usage statistics

The blue line displays unique views in the time frame indicated.
The yellow line displays unique downloads.
Views and downloads are counted only once per session.

No supplementary material is available for this article.